News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

July 8, 2024

FDA Approves Genentech’s Vabysmo Prefilled Syringe to Treat Wet Age-Related Macular Degeneration, Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion

Author(s):

Don Tracy, Associate Editor

The Vabysmo prefilled syringe is designed to simplify administration for retina specialists, improving the treatment experience for both physicians and patients with wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.

Colorful eye. Image Credit: Adobe Stock Images/irishmaster

Image Credit: Adobe Stock Images/irishmaster

The FDA has approved Genentech’s Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). According to the company, the PFS format was developed to streamline the administration process, resulting in a smoother treatment experience for both physicians and patients. The PFS version of the treatment offers the same medication as the current Vabysmo vials in a ready-to-use form. Genentech noted that Vabysmo is the first bispecific antibody approved for the eye.1

“We are pleased that the US FDA has approved the Vabysmo PFS for people living with wet AMD, DME and RVO, which are some of the leading causes of vision loss,” said Levi Garraway, MD, PhD, chief medical officer, head of Global Product Development, Genentech, in a press release. “While many retina specialists are already using Vabysmo as a first-line treatment, this new offering should make it even simpler to administer, thereby enhancing the treatment experience for both physicians and patients.”

Vabysmo targets and inhibits two signaling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Currently, research is ongoing to understand the role of the Ang-2 pathway in retinal disease, with the hypothesis that Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels.

The most common adverse events (AEs) reported in patients treated with Vabysmo were cataracts and blood on the white of the eye. Genentech warns that the treatment could pose a risk to unborn babies, further suggesting that patients should use birth control before, during, and for three months after their last dose of Vabysmo. Additionally, it is currently unknown whether Vabysmo passes into breast milk. It can also result in a temporary increase in pressure in the eye one hour after injection, can cause eye infections, retinal vasculitis, retinal vascular occlusion, and, in rare cases, fatal issues such as heart attacks or strokes.1

Current treatments for macular degeneration include medical injections to the eye to prevent leaky blood vessels from forming, laser therapy, photodynamic therapy, submacular surgery, vitamins, and retinal translocation. It can be prevented through eating vegetables high in carotenoids, refraining from smoking, wearing sunglasses with an ultraviolet filter, and keeping up with visits to an eye care specialist.2

“Conventional treatment for disorders such as nearsightedness, farsightedness, and astigmatism typically relies on corrective prescription lenses,” reports WebMD. “Disorders such as cataracts, glaucoma, macular degeneration, and retinal detachment require advanced medical and surgical treatments. Enormous progress in eye surgery has been made over the past few decades. Many people with eye problems previously felt to be untreatable now enjoy improved eyesight and an improved quality of life.”

The Centers for Disease Control and Prevention (CDC) also recommends frequently washing hands before putting in contact lenses as well as cleaning them properly. Additionally, maintaining a healthy weight will help prevent the development of chronic conditions such as type 2 diabetes, which could result in eye damage. The CDC states that 90% of blindness caused by diabetes is avoidable by maintaining a health blood sugar level.3

Vabysmo, which was first approved in the United States in 2022, is approved in 95 countries for the treatment of wet AMD and DME, and in a number of countries for RVO as well. Currently, the treatment is under review by governing health agencies across the globe.1

References

1. FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss. Genentech. July 4, 2024. Accessed July 8, 2024. https://www.gene.com/media/press-releases/15030/2024-07-04/fda-approves-genentechs-vabysmo-prefille

2. Understanding Vision Problems – Treatment. WebMD. March 13, 2024. Accessed July 8, 2024. https://www.webmd.com/eye-health/understanding-vision-problems-treatment

3. Preventing Vision Loss. CDC. Accessed July 8, 2024. https://www.cdc.gov/vision-health/prevention/index.html

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Related Content
Advertisement
Stock.adobe.com
August 1st 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 1st 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.
Navigating Distrust: Pharma in the Age of Social Media
August 1st 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Stock.adobe.com
August 1st 2025

Report Says President Trump Pushed for Vinay Prasad’s Removal

Mike Hollan
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
President Donald Trump
August 1st 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
Related Content
Advertisement
Stock.adobe.com
August 1st 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 1st 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.
Navigating Distrust: Pharma in the Age of Social Media
August 1st 2025

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Stock.adobe.com
August 1st 2025

Report Says President Trump Pushed for Vinay Prasad’s Removal

Mike Hollan
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
President Donald Trump
August 1st 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.